Skip to main content Skip to search Skip to main navigation

EC: IVDR for In-vitro-Diagnostic Medical Devices Entered into Force

After a one-year postponement period, the European In Vitro Diagnostic Medical Devices Regulation (IVDR) finally came into force on 26 May 2022 and follows the Medical Device Regulation (MDR), which has been in force for one year.

Thus, these medical device directives valid until that date will cease to apply:

  • Directive on Active Implantable Medical Devices 90/385/EEC (AIMD)
  • Directive on Medical Devices 93/42/EEC (MDD)
  • Directive on in vitro diagnostic medical devices 98/79/EC (IVDD).


With the entry into force of the IVDR, the dates for transition periods have been partially adjusted:

25 May 2022-26 May 2025
Certificates still issued under the IVDD can remain valid until 26 May 2025; however, all Class D devices placed on the market after 26 May 2025 must be fully compliant with the IVDR.

By 26 May 2026
All Class C devices placed on the market after 26 May 2026 must be fully compliant with the IVDR.

26 May 2027
All class B devices and class A sterile devices placed on the market after 26 May 2027 must be fully compliant with the IVDR.

Continued without change from 26 May 2022
All non-sterile class A devices placed on the market after 25 May 2022 must be fully compliant with the IVDR. All new devices placed on the market must comply with the IVDR.


Source:
EC: In Vitro Diagnostic Medical Devices Regulation (IVDR)

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

What Types of Impurities may be Present in Active Substances?

What Types of Impurities may be Present in Active Substances?


Read more
There’s Something in the Air – Cleanroom Technology in the Pharmaceutical Industry

There’s Something in the Air – Cleanroom Technology in the Pharmaceutical Industry

In pharmaceutical manufacturing, clean air is not a subjective perception but a precisely controlled technical condition that is essential for product safety. Heating, ventilation and air-conditioning (HVAC) systems ensure, through airflow management, air filtration and pressure control, that particles and microorganisms are kept away from critical areas. This is based on clearly defined requirements for air changes, cleanliness classes, airflow patterns and pressure concepts, all of which are designed according to the manufacturing process and contamination risk involved.
Read more
EU: Analysis Supporting the Proposed Biotech Act

EU: Analysis Supporting the Proposed Biotech Act

The European Commission has published the analysis underpinning the proposed Biotech Act. The initiative aims to strengthen Europe’s biotechnology and biomanufacturing sectors and to accelerate the development, production and market uptake of biotechnology-based innovations.
Read more
EFPIA: Results of the Member Survey 2025 on GMP and GDP Inspections

EFPIA: Results of the Member Survey 2025 on GMP and GDP Inspections

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published the results of its “Annual Regulatory GMP/GDP Inspection Survey 2025”. The data suggest that international GMP inspections are increasingly being replaced by reliance and work-sharing approaches between inspectorates.
Read more
What are the Core Tasks of Human Resource Management?

What are the Core Tasks of Human Resource Management?

Here's the answer:
Read more
European GMP Regulations: Ongoing Changes and What Lies Ahead

European GMP Regulations: Ongoing Changes and What Lies Ahead

At the 2026 ISPE European Annual Conference in Copenhagen, Brendan Cuddy (EMA) provided a concise update on current European GMP regulatory developments and the work of the GMP/GDP Inspectors Working Group (GMDP IWG).
Read more
Previous
Next